Lyell Immunopharma
LYEL
93 hedge funds and large institutions have $823M invested in Lyell Immunopharma in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 4 closing their positions.
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
127% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 15
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
24% more funds holding
Funds holding: 75 → 93 (+18)
20% more capital invested
Capital invested by funds: $689M → $823M (+$135M)
0.12% more ownership
Funds ownership: 2.15% → 2.27% (+0.12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$18.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12M |
| 3 |
BlackRock
New York
|
+$11.7M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.27M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$5.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$22.2M |
| 2 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$10.7M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.09M |
| 4 |
SG Americas Securities
New York
|
-$275K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$151K |
LYEL Hedge Fund Activity: Q3 2022 in Review
93 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q3 2022, worth a combined $823M — up 20% from $689M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new LYEL positions and 4 closed out — a net gain of 18 holders — while 34 added to existing stakes and 15 trimmed.
The largest buyer was State Street, adding an estimated $18.8M. The largest seller was Foresite Capital Management IV, cutting an estimated $22.2M.
- 93 institutional investors held Lyell Immunopharma (LYEL) as of Q3 2022, up from 75 in Q2 2022.
- Funds reported $823M of Lyell Immunopharma stock for Q3 2022, up 20% quarter-over-quarter.
- 22 funds opened new Lyell Immunopharma positions in Q3 2022 and 4 closed out, a net change of +18 holders.
- The largest Lyell Immunopharma buyer in Q3 2022 was State Street, an estimated $18.8M added.
- The largest Lyell Immunopharma seller in Q3 2022 was Foresite Capital Management IV, an estimated $22.2M sold.
Based on aggregated 13F filings for Q3 2022.